Tibotec Pharmaceuticals' protease inhibitor darunavir [PREZISTA] has received conditional marketing authorisation from the European Commission

Source: Inpharma, Volume 1, Number 1576, 2007-02-24 , pp. 23-23(1)

Keywords: Darunavir, therapeutic use; Development-status; HIV-1-infections, treatment; Research-and-development; Tibotec-Pharmaceuticals

Document Type: Short communication

Links for this article

http://www.ingentaconnect.com/adis/inp/2007/00000001/00001576/art00073
http://openurl.ingenta.com/content?genre=article&issn=1173-8324&volume=1&issue=1576&spage=23&epage=23